PMID- 22065075
OWN - NLM
STAT- MEDLINE
DCOM- 20130517
LR  - 20211021
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 11
DP  - 2012 Nov
TI  - A case of leukoencephalopathy associated with adalimumab-treated rheumatoid 
      arthritis and a review of literature.
PG  - 3481-5
LID - 10.1007/s00296-011-2216-0 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitor is recently being widely used 
      to treat autoimmune diseases, but some noticeable adverse events were reported 
      and neurological events have especially been described. It is mandatory to 
      compare these cases for finding the risk factors, the duration of the 
      neurological events, their processes and their outcomes. We present here the case 
      of leukoencephalopathy secondary to adalimumab, which is a tumor necrosis factor 
      alpha (TNF-alpha) inhibitor. We also reviewed the other 14 published leukoencephalopathy 
      cases associated with the use of TNF inhibitors. Eleven patients had underlying 
      rheumatoid arthritis, and the others had psoriatic arthritis, ankylosing 
      spondylitis and Still's disease. The median duration of treatment with anti-TNF-alpha 
      before the presentation of neurological symptoms was 9.2 months (range: 1.5-24). 
      The duration of using anti-TNF-alpha was not related with the outcome. Although cases 
      of neurological adverse events associated with anti-TNF-alpha treatment are rare, it 
      is very important to monitor the neurological signs and symptoms suggestive of a 
      demyelinating disorder in RA patients who are receiving anti-TNF-alpha treatment and 
      especially those patients who are older and who have a history of MS or 
      demyelination.
FAU - Ryu, Yang-Seon
AU  - Ryu YS
AD  - Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Park, Sung-Hwan
AU  - Park SH
FAU - Kim, Ji-Min
AU  - Kim JM
FAU - Kim, Eun-Ji
AU  - Kim EJ
FAU - Lee, Jennifer
AU  - Lee J
FAU - Kwok, Seung-Ki
AU  - Kwok SK
FAU - Ju, Ji-Hyeon
AU  - Ju JH
FAU - Kim, Ho-Youn
AU  - Kim HY
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111108
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
CIN - Z Rheumatol. 2013 Feb;72(1):5. PMID: 23520635
MH  - Adalimumab
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Antirheumatic Agents/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/pathology
MH  - Humans
MH  - Leukoencephalopathies/*chemically induced/pathology
MH  - Male
MH  - Nerve Fibers, Myelinated/*pathology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2011/11/09 06:00
MHDA- 2013/05/18 06:00
CRDT- 2011/11/09 06:00
PHST- 2011/07/05 00:00 [received]
PHST- 2011/10/22 00:00 [accepted]
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2013/05/18 06:00 [medline]
AID - 10.1007/s00296-011-2216-0 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Nov;32(11):3481-5. doi: 10.1007/s00296-011-2216-0. Epub 2011 
      Nov 8.